304 related articles for article (PubMed ID: 33768008)
1. Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter.
Kordella C; Lamprianidou E; Kotsianidis I
Front Oncol; 2021; 11():650473. PubMed ID: 33768008
[TBL] [Abstract][Full Text] [Related]
2. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract][Full Text] [Related]
3. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.
Wolff F; Leisch M; Greil R; Risch A; Pleyer L
Cell Commun Signal; 2017 Mar; 15(1):13. PubMed ID: 28359286
[TBL] [Abstract][Full Text] [Related]
4. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Wong KK; Hassan R; Yaacob NS
Front Oncol; 2021; 11():624742. PubMed ID: 33718188
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
[TBL] [Abstract][Full Text] [Related]
7. Decitabine Induces Gene Derepression on Monosomic Chromosomes:
Greve G; Schüler J; Grüning BA; Berberich B; Stomper J; Zimmer D; Gutenkunst L; Bönisch U; Meier R; Blagitko-Dorfs N; Grishina O; Pfeifer D; Weichenhan D; Plass C; Lübbert M
Cancer Res; 2021 Feb; 81(4):834-846. PubMed ID: 33203699
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
Madanat Y; Sekeres MA
Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
[TBL] [Abstract][Full Text] [Related]
9. 5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia.
Ebelt ND; Manuel ER
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612115
[TBL] [Abstract][Full Text] [Related]
10. [Markers for Predicting Response to Hypomethylating Agents in MDS and AML Patients].
Chen XP; Jing Y; Li YH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1769-73. PubMed ID: 26708908
[TBL] [Abstract][Full Text] [Related]
11. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis.
Zheng X; Lv L; Li X; Jiang E
Glob Med Genet; 2022 Jun; 9(2):141-151. PubMed ID: 35707788
[No Abstract] [Full Text] [Related]
13. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
14. The use of hypomethylating agents in hematologic malignancies: treatment preferences and results.
Serin I; Dogu MH
Int J Hematol Oncol; 2021 Dec; 10(4):IJH37. PubMed ID: 35295753
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
Hur EH; Jung SH; Goo BK; Moon J; Choi Y; Choi DR; Chung YJ; Lee JH
Oncotarget; 2017 Feb; 8(7):11748-11762. PubMed ID: 28052028
[TBL] [Abstract][Full Text] [Related]
17. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
Zeidan AM; Stahl M; Sekeres MA; Steensma DP; Komrokji RS; Gore SD
Cancer; 2017 Oct; 123(19):3662-3672. PubMed ID: 28759108
[TBL] [Abstract][Full Text] [Related]
18. Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism.
Zhao G; Wang Q; Li S; Wang X
Front Oncol; 2021; 11():706030. PubMed ID: 34650913
[TBL] [Abstract][Full Text] [Related]
19. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
Komrokji RS
Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells.
Choi EJ; Koo BK; Hur EH; Moon JH; Kim JY; Park HS; Choi Y; Lee KH; Lee JH; Choi EK; Lee JH
Biomol Ther (Seoul); 2023 May; 31(3):319-329. PubMed ID: 36382510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
